Intracavernous Injection of Prostaglandin E1 in Impotent Men

Stackl, W.; Hasun, R.; Marberger, Michael

doi:10.1016/s0022-5347(17)41488-1

Cited by 166 publications

(32 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although intracavernous injection therapy [1][2][3][4] and penile prostheses 5 offer reliable therapeutic options for most patients with erectile dysfunction, these alternatives are often rejected for various reasons. This rejection is reflected by dropout rates of 50% or more in some longitudinal studies following patients on auto-injection therapy or by low overall acceptance rates of penile prosthesis implantation.…”

Section: A16mentioning

confidence: 99%

Prognostic Factors for the Postoperative Outcome of Penile Venous Surgery for Venogenic Erectile Dysfunction

et al. 1994

View full text Add to dashboard Cite

Section: A16mentioning

confidence: 99%

Prognostic Factors for the Postoperative Outcome of Penile Venous Surgery for Venogenic Erectile Dysfunction

et al. 1994

View full text Add to dashboard Cite

“…Erection began in normal time, that is 9.4 min, and its duration was about one hour, which is less than reported previously. 3,5,15 Almost all instances of intercourse succeeded at home with PGE1. At work, the Rigiscan measurement with the home dose of PGE1 also showed the erection to be fairly good (the mean maximal rigidity was 53.5% at the base and 56.6% at the tip of the penis).…”

Section: Discussionmentioning

confidence: 98%

“…PGE1 causes a pharmacologic erection, which is highly dose-dependent and therefore has a low rate of priapism. 4,5 There have also been only a few cases of ®brosis in PGE1 users. 2 ± 4 Prolonged pain is quite common with PGE1, having been noted in 9.4 ± 34% of the patients using PGE1 alone.…”

Section: Introductionmentioning

confidence: 99%

Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction

Kunelius

Lukkarinen

1999

Int J Impot Res

View full text Add to dashboard Cite

In a three-year follow-up study of 69 patients found that erectile dysfunction (ED) impairs many elderly men's life: up to 25% of the men aged 65 y and 80% of those aged 75 y suffer from erectile dysfunction. The most effective non-surgical treatment of ED is intracavernosal pharmacotherapy, and the most common vasoactive agent currently used is prostaglandin E1 (PGE1). The purpose of this study was to assess the long-term outcome of PGE1 treatment and the patients' overall satisfaction with their sexual life.Sixty-nine patients who had started ICI therapy three years earlier were invited to a control examination. The mean age of the patients was 60.5 y. The patients ®lled in a questionnaire, which included questions about the use of PGE1 treatment at home. All the patients evaluated their own satisfaction with their erection, ejaculation, orgasm and libido on a visual analytical scale (VAS, 0 ± 100%). A clinical examination was made, and the penile shaft was examined by ultrasonography. Erection with the home dose of PGE1 was estimated by Rigiscan, and the degree of erection was also estimated clinically (grades 0 ± 5) by a doctor.The most common doses of PGE1 used at home were between 10 and 20 m (58%), 46.4% of the patients had discontinued PGE1 therapy, the mean time of using PGE1 was 23.3 months. The mean coital frequency with PGE1 was 2.8 times per month. 34.8% of the patients (24 out of 69) reported that their own spontaneous erections had improved after the beginning of PGE1 therapy. The most common problem was hematomas in 10.1% of the patients (7 out of 69), which, however, were small and did not cause discontinuation of the therapy. There were three instances of priapism (4.3%), and four patients (5.8%) had ®brosis in ultrasonography. The patients' satisfaction with their erection at home was 67.3% with PGE1.The mean coital frequency with PGE1 therapy was quite low, 2.8 times per month, even though the patients' mean age was only 60.5 y, one reason may be the high price of PGE1 injections. The rate of improvement of spontaneous erections while using PGE1 was quite high, accounting for 34.8% of the patients. Most of the patients who discontinued the PGE1 therapy had a psychogenic etiology. There were no systemic side-effects with PGE1. Only 7.2% of the patients had prolonged pain after the injection, leading to drug discontinuation.It can be concluded that treatment with intracavernous injections of PGE1 is well tolerated and involves only minor problems. The patients' satisfaction with their erections at home with PGE1 therapy was good. Precise determination of the home dose of PGE1 and the teaching of the technique of injection are important at the beginning of this treatment modality.

show abstract

“…Since that time, the publications of its efficacy and demonstrated safety in larger population groups have paved the way for worldwide acceptance of alprostadil in both office use and self-injection therapy. 4 PGE 1 is a potent smooth-muscle relaxant, which induces relaxation of isolated human penile erectile tissue and cavernous arteries. 5 The convincing efficacy of alprostadil is attributed to several pharmacological properties of the drug: stimulation of the adenylate cyclase with intracellular accumulation of cAMP and subsequent intracellular calcium decrease; direct stimulation of the maxi potassiumchannels resulting in hyperpolarization; inhibition of the noradrenalin release via presynaptic alpha1 adrenoceptors, resulting in a decrease of sympathetic tone; and suppression of angiotensin II secretion.…”

Section: Introductionmentioning

confidence: 99%

Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction

El‐Sakka

2005

Int J Impot Res

View full text Add to dashboard Cite

We have investigated the reliability of intracavernosal prostaglandin E 1 (PGE 1 ) office vs selfinjection therapy in patients with erectile dysfunction (ED). A total of 298 male patients with ED were enrolled in this study. In all patients, intracavernosal titration of the PGE 1 dose was performed. A total of 106 patients were enrolled in the self-injection program, and 192 patients were enrolled in the office injection program. There were significant differences between number of injections and amount of PGE 1 per month, total number of injections, and total amount of PGE 1 on office and self-injection programs (Po0.05 for each). There was a significant increase in the dropout rate in the office injection group compared with the self-injection group (Po0.05). There was an increase in penile fibrosis in the self-injection program compared with the office program (Po0.05). A self-injection program is reliable. Office injection program can be reserved for a subset of ED patients with special preferences.

show abstract

Intracavernous Injection of Prostaglandin E1 in Impotent Men

Cited by 166 publications

References 12 publications

Prognostic Factors for the Postoperative Outcome of Penile Venous Surgery for Venogenic Erectile Dysfunction

Prognostic Factors for the Postoperative Outcome of Penile Venous Surgery for Venogenic Erectile Dysfunction

Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction

Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction

Contact Info

Product

Resources

About